{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:42:40Z","timestamp":1760820160119,"version":"3.44.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.jns.2009.10.009","type":"journal-article","created":{"date-parts":[[2009,11,9]],"date-time":"2009-11-09T04:06:03Z","timestamp":1257739563000},"page":"178-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Central nervous system inflammatory demyelination after rituximab therapy for idiopathic thrombocytopenic purpura"],"prefix":"10.1016","volume":"288","author":[{"given":"Joerg-Patrick","family":"St\u00fcbgen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2009.10.009_bib1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion on B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jns.2009.10.009_bib2","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jns.2009.10.009_bib3","first-page":"519","article-title":"Effective B cell depletion with rituximab in the treatment of autoimmune diseases","volume":"206","author":"Kneitz","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.jns.2009.10.009_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00296-007-0471-x","article-title":"The potential utility of B cell-targeted biologic therapy in autoimmune diseases","volume":"28","author":"Arkfield","year":"2008","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jns.2009.10.009_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"G\u00fcrcan","year":"2008","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jns.2009.10.009_bib6","first-page":"207","article-title":"Chronic idiopathic thrombocytopenic purpura","volume":"331","author":"George","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2009.10.009_bib7","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituxiamb chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jns.2009.10.009_bib8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00277-007-0317-3","article-title":"Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis","volume":"86","author":"Garcia-Chavez","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jns.2009.10.009_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-0609.2008.01100.x","article-title":"Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long term follow-up results","volume":"81","author":"Medeot","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jns.2009.10.009_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K","article-title":"Approaches for identifying and defining environmentally associated rheumatic disorders","volume":"43","author":"Miller","year":"2000","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jns.2009.10.009_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2008.07.019","article-title":"B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders","volume":"204","author":"St\u00fcbgen","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jns.2009.10.009_bib12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2169\/internalmedicine.44.747","article-title":"Multiple sclerosis following splenectomy as treatment for idiopathic thrombocytopenic purpura","volume":"44","author":"Matsui","year":"2005","journal-title":"Intern Med"},{"key":"10.1016\/j.jns.2009.10.009_bib13","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2009.10.009_bib14","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1212\/01.wnl.0000221747.37657.c6","article-title":"The lumping and splitting of inflammatory CNS disease","volume":"66","author":"Kerr","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2009.10.009_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/WCO.0b013e3280be58d8","article-title":"Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis","volume":"20","author":"Wingerchuk","year":"2007","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.jns.2009.10.009_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458508098268","article-title":"Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders","volume":"15","author":"Petereit","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2009.10.009_bib17","series-title":"McAlpine's multiple sclerosis","first-page":"491","article-title":"The immunology of inflammatory demyelinating disease","author":"Wekerle","year":"2006"},{"key":"10.1016\/j.jns.2009.10.009_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","article-title":"Rituximab reduces B cells and T cells in the cerebrospinal fluid of multiple sclerosis patients","volume":"180","author":"Cross","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jns.2009.10.009_bib19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clim.2008.01.011","article-title":"Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells","volume":"127","author":"Liossis","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jns.2009.10.009_bib20","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jns.2009.10.009_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-5728(92)90188-Q","article-title":"Synergy between encephalitogenic T cells and myelin basic protein-specific antibodies in the induction of experimental autoimmune encephalomyelitis","volume":"41","author":"Myers","year":"1992","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jns.2009.10.009_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2006.06.032","article-title":"Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment","volume":"180","author":"Antel","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jns.2009.10.009_bib23","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.wco.0000313359.61176.15","article-title":"The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies","volume":"21","author":"Racke","year":"2008","journal-title":"Curr Opin Neurol"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X09009058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X09009058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:40:50Z","timestamp":1758382850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X09009058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":23,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0022510X09009058"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2009.10.009","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central nervous system inflammatory demyelination after rituximab therapy for idiopathic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2009.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}